Choroidal hemangioma treated with photodynamic therapy using verteporfin

Arch Ophthalmol. 2001 Nov;119(11):1606-10. doi: 10.1001/archopht.119.11.1606.


Objective: To describe a new treatment for vision loss caused by subretinal fluid associated with circumscribed choroidal hemangioma.

Methods: Three patients were treated with photodynamic therapy using verteporfin for injection (Visudyne; QLT Phototherapeutics Inc, Vancouver, British Columbia). All patients had pretreatment and posttreatment fluorescein angiography and ultrasonography. Treatment parameters used were verteporfin, 6 mg/m(2), and laser light at 689 nm delivered at 50 J/cm(2) with an intensity of 600 mW/cm(2) for 83 seconds.

Results: All patients had complete resolution of subretinal fluid within 2 weeks of treatment. Fluorescein angiography performed 2 to 4 weeks after treatment showed absence of tumor leakage. All eyes had reduced tumor thickness or complete flattening. Visual acuity was improved in each eye. Average follow-up was 5.3 months. No complications were noted.

Conclusion: Photodynamic therapy with verteporfin is effective in eliminating subretinal fluid and improving vision in patients with circumscribed choroidal hemangioma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Choroid Neoplasms / diagnostic imaging
  • Choroid Neoplasms / drug therapy*
  • Female
  • Fluorescein Angiography
  • Fundus Oculi
  • Hemangioma, Capillary / diagnostic imaging
  • Hemangioma, Capillary / drug therapy*
  • Humans
  • Male
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use*
  • Porphyrins / therapeutic use*
  • Treatment Outcome
  • Ultrasonography
  • Verteporfin
  • Visual Acuity


  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin